Sibling brands, one platform: the real differences are audience positioning and product framing, not pharmacology — which makes this the market’s clearest lesson in comparing marketing to substance.
The two models
Hims is the category’s marketing heavyweight with its most contested model: after its Novo Nordisk partnership collapsed in June 2025, it leaned into “personalized” compounded semaglutide — the legal rationale regulators and manufacturers dispute most directly. Advertised entry prices are aggressive; true maintenance-dose totals are exactly what our pending verification exists to establish.
Hers is Hims’ women-focused sibling, sharing the platform, the post-Novo compounded “personalization” posture, and the aggressive entry pricing — wrapped in women’s-health positioning. The same questions apply: maintenance-dose truth, fee stack, and legal lane, all pending verification in our queue.
Verified vs pending — read this before the marketing
Neither provider on this page has completed price verification, so this comparison stays structural — business models, pricing architecture, and the questions each must answer — with zero advertised numbers repeated as facts. The only verified figures on this site today sit in the ledger.
Same engine, different paint
Both ride the post-Novo “personalization” compounding rationale, both advertise aggressive entry pricing, both remain unverified in our queue. A shopper choosing between them is mostly choosing a storefront; the questions that matter — maintenance-dose truth, fee stack, legal lane (context) — are identical and identically open.
Go deeper
Full files: Hims · Hers. Decision tools: the quiz routes by coverage and priorities; the calculator turns any quote into a true 12-month number; the ledger holds every verified figure and every pending slot.